Data supporting prostate-specific antigen screening show that the trade-off between harm and benefit is more favorable with a complementary approach to quantifying overdiagnosis. According to the...
Bobby Riau, MD: We usually evaluate the effectiveness of prostate cancer treatment in three ways: symptoms, PSA. [prostate-specific antigen tests], And imaging. I usually repeat this...
David Alvara, MD: Hello, nice to meet you Uro View™ Video Series “The Role of Liquid Biomarkers for Early Detection of Prostate Cancer”. I’m Dr. David...
COLORADO SPRINGS — Follow-up to the last story Prostate foundationNow that we know where it is and what it serves for, why is the conversation about...
Recent Comments